ClinicalTrials.gov
ClinicalTrials.gov Menu

AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01107340
Recruitment Status : Active, not recruiting
First Posted : April 20, 2010
Last Update Posted : May 8, 2018
Sponsor:
Information provided by (Responsible Party):
Medacta International SA

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.

Condition or disease Intervention/treatment Phase
Osteoarthritis Arthritis Avascular Necrosis Fracture of the Femoral Neck or Head Congenital Hip Dysplasia Device: AMIStem Hip System Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study
Study Start Date : February 2010
Estimated Primary Completion Date : February 2028
Estimated Study Completion Date : February 2028

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
AMIStem Hip System
Patients who comply with the protocol and received an AMIStem femoral component.
 Device: AMIStem Hip System


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Assessment of implant survivorship using Kaplan Meier curve [ Time Frame: 10 years after surgery ]

Secondary Outcome Measures :
  1. Assessment of the patient's physical level of activity using the Oxford Hip Score [ Time Frame: pre-op, annually post-op up to 10 years ]
  2. Assessment of the improvement in quality of life and joint movement using the EuroQol-5D score [ Time Frame: pre-op, annually post-op up to 10 years ]
  3. Assessment of implant survivorship as a measure of safety using Kaplan Meier curve [ Time Frame: 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ]
  4. Assessment of the clinical outcome following total hip replacement using the Harris Hip Score [ Time Frame: pre-op, 6 months, 3 years, 5 years, 7.5 years, 10 years after surgery ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System
  • Patient is willing and able to give informed consent to participate in the follow-up program
  • Patient is suitable for surgery and able to participate in the follow-up program.
  • Those presenting with disease that meets the indication for use for Medacta implants defined in the study (on-label use)

Exclusion Criteria:

  • Acute systemic or chronic infection
  • Skeletal immaturity
  • Severe muscular, neurological, vascular deficiency or other pathologies of the affected limb that may compromise the stability of the implant.
  • Bone condition that may compromise the stability of the implant.
  • Patient who are unwilling or unable to give consent, or to comply with the protocol and the follow-up program.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01107340


Locations
Switzerland
Uniklinik Balgrist
Zurich, Switzerland, 8008
United Kingdom
The Elective Orthopaedic Centre (EOC)
Epsom, Surrey, United Kingdom, KT18 7EG
Sponsors and Collaborators
Medacta International SA
Investigators
Principal Investigator: Richard E Field, PhD FRCS(Orth) British Orthopaedic Association
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Medacta International SA
ClinicalTrials.gov Identifier: NCT01107340     History of Changes
Other Study ID Numbers: P01.004.11
First Posted: April 20, 2010    Key Record Dates
Last Update Posted: May 8, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Osteoarthritis
Necrosis
Hip Dislocation
Hip Dislocation, Congenital
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
 Pathologic Processes
Joint Dislocations
Bone Diseases
Wounds and Injuries
Hip Injuries
Musculoskeletal Abnormalities
Congenital Abnormalities